{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:48:48Z","timestamp":1789642128629,"version":"4.0.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FTLDc O1GI1007A"],"award-info":[{"award-number":["FTLDc O1GI1007A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["MND-Net 01GM1103A"],"award-info":[{"award-number":["MND-Net 01GM1103A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008316","name":"Baden-W\u00fcrttemberg Stiftung","doi-asserted-by":"publisher","award":["D.3830"],"award-info":[{"award-number":["D.3830"]}],"id":[{"id":"10.13039\/100008316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019787","name":"Sophia University","doi-asserted-by":"publisher","award":["01ED1202A"],"award-info":[{"award-number":["01ED1202A"]}],"id":[{"id":"10.13039\/100019787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019787","name":"Sophia University","doi-asserted-by":"publisher","award":["BiomarkAPD 01ED1203F"],"award-info":[{"award-number":["BiomarkAPD 01ED1203F"]}],"id":[{"id":"10.13039\/100019787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019787","name":"Sophia University","doi-asserted-by":"publisher","award":["NADINE 246513"],"award-info":[{"award-number":["NADINE 246513"]}],"id":[{"id":"10.13039\/100019787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.bbapap.2014.12.010","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T20:33:08Z","timestamp":1418761988000},"page":"757-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives"],"prefix":"10.1016","volume":"1854","author":[{"given":"Patrick","family":"Oeckl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Feneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2014.12.010_bb0005","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00018-012-0957-x","article-title":"The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond","volume":"69","author":"Zappaterra","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-4-8","article-title":"The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease","volume":"4","author":"Golde","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0020","first-page":"3","article-title":"Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration","volume":"36","author":"Feneberg","year":"2012","journal-title":"J. Lab. Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrm3810","article-title":"The amyloid state and its association with protein misfolding diseases","volume":"15","author":"Knowles","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0030","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00702-009-0240-y","article-title":"Recent advances in our understanding of neurodegeneration","volume":"116","author":"Jellinger","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0035","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/11640070-000000000-00000","article-title":"Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management","volume":"26","author":"Seltman","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0040","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamaneurol.2013.114","article-title":"Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism","volume":"70","author":"Savica","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","article-title":"Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management","volume":"24","author":"Rabinovici","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00401-012-1029-x","article-title":"The genetics and neuropathology of frontotemporal lobar degeneration","volume":"124","author":"Sieben","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","article-title":"A harmonized classification system for FTLD\u2013TDP pathology","volume":"122","author":"Mackenzie","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000110576","article-title":"A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia","volume":"24","author":"Simonsen","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0065","first-page":"757","article-title":"Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia","volume":"1","author":"Mattsson","year":"2008","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.expneurol.2005.08.002","article-title":"Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF","volume":"196","author":"R\u00fcetschi","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.parkreldis.2010.06.011","article-title":"Proteomic profiling of cerebrospinal fluid in parkinsonian disorders","volume":"16","author":"Constantinescu","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0169-328X(02)00549-1","article-title":"Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins","volume":"109","author":"Davidsson","year":"2002","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-5956-2-7","article-title":"Validation of a prefractionation method followed by two-dimensional electrophoresis \u2014 applied to cerebrospinal fluid proteins from frontotemporal dementia patients","volume":"2","author":"Hansson","year":"2004","journal-title":"Proteome Sci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0090","doi-asserted-by":"crossref","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","article-title":"Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers","volume":"6","author":"Jahn","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0095","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1093\/hmg\/ddt349","article-title":"Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD\u2013ALS spectrum disorders","volume":"22","author":"Janssens","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0100","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/archneur.65.11.1481","article-title":"TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"65","author":"Steinacker","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0105","first-page":"1","article-title":"Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases","author":"Feneberg","year":"2014","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0110","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp-2013-305972","article-title":"Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation","volume":"85","author":"Su\u00e1rez-Calvet","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tem.2013.08.003","article-title":"Progranulin: at the interface of neurodegenerative and metabolic diseases","volume":"24","author":"Nguyen","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0120","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","article-title":"Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration","volume":"71","author":"Ghidoni","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1083\/jcb.200712039","article-title":"Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival","volume":"181","author":"Van Damme","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0130","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/NEN.0b013e3181fc9aea","article-title":"Microglial upregulation of progranulin as a marker of motor neuron degeneration","volume":"69","author":"Philips","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bpa.12044","article-title":"\u201cPrion-like\u201d templated misfolding in tauopathies","volume":"23","author":"Clavaguera","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0140","first-page":"297","article-title":"Frontotemporal lobar degeneration: current perspectives","volume":"10","author":"Riedl","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnagi.2013.00006","article-title":"Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease","volume":"5","author":"Irwin","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0150","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/CCLM.2011.086","article-title":"Tau and p-tau as CSF biomarkers in dementia: a meta-analysis","volume":"49","author":"van Harten","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1471-4159.2012.07911.x","article-title":"Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies","volume":"123","author":"Luk","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0170","doi-asserted-by":"crossref","first-page":"a006247","DOI":"10.1101\/cshperspect.a006247","article-title":"Biochemistry and cell biology of tau protein in neurofibrillary degeneration","volume":"2","author":"Mandelkow","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0180","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0185","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0190","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","article-title":"A novel pathway for amyloid precursor protein processing","volume":"32","author":"Portelius","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0195","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0197-4580(00)00173-1","article-title":"Quantitative neurohistological features of frontotemporal degeneration","volume":"21","author":"Arnold","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0200","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00702-007-0629-4","article-title":"Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?","volume":"114","author":"Mollenhauer","year":"2007","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.mp.4001967","article-title":"Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias","volume":"12","author":"Bibl","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00702-006-0618-z","article-title":"Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations","volume":"114","author":"Bibl","year":"2007","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0215","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00702-012-0801-3","article-title":"Cerebrospinal fluid amyloid-\u03b2 2\u201342 is decreased in Alzheimer's, but not in frontotemporal dementia","volume":"119","author":"Bibl","year":"2012","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0220","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/prca.200800006","article-title":"CSF amyloid-\u03b2 1\u201338 and 1\u201342 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction","volume":"2","author":"Bibl","year":"2008","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000322370","article-title":"Cerebrospinal fluid tau, p-tau 181 and amyloid-\u03b238\/40\/42 in frontotemporal dementias and primary progressive aphasias","volume":"31","author":"Bibl","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0230","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JAD-2011-110515","article-title":"Decreased sA\u03b2PP\u03b2, A\u03b238, and A\u03b240 cerebrospinal fluid levels in frontotemporal dementia","volume":"26","author":"Gabelle","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0235","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00702-009-0271-4","article-title":"Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration","volume":"116","author":"Steinacker","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0240","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-2009-0966","article-title":"Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients","volume":"16","author":"Hansson","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0245","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jnnp.2006.105064","article-title":"Decreased cerebrospinal fluid amyloid beta (1\u201340) levels in frontotemporal lobar degeneration","volume":"78","author":"Pijnenburg","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2009.06.011","article-title":"Quantification of amyloid-beta 40 in cerebrospinal fluid","volume":"348","author":"Verwey","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0255","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3233\/JAD-2010-1392","article-title":"Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects","volume":"20","author":"Verwey","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-2008-14102","article-title":"Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia","volume":"14","author":"Gloeckner","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12017-012-8208-8","article-title":"A\u03b21\u201315\/16 as a potential diagnostic marker in neurodegenerative diseases","volume":"15","author":"Nutu","year":"2013","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt30","article-title":"A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease","volume":"2","author":"Portelius","year":"2010","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.0b013e318221ad47","article-title":"CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease","volume":"77","author":"Perneczky","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0280","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-140240","article-title":"Relationship between \u03b2-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease","volume":"42","author":"Alcolea","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0285","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3940(99)00631-X","article-title":"Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease","volume":"273","author":"Kimura","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0290","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3233\/JAD-2011-110983","article-title":"Interrelations between CSF soluble A\u03b2PP\u03b2, amyloid-\u03b2 1\u201342, SORL1, and tau levels in Alzheimer's disease","volume":"28","author":"Alexopoulos","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000051268","article-title":"The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process","volume":"12","author":"Sj\u00f6gren","year":"2001","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0300","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0305","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/j.1460-9568.2008.06165.x","article-title":"Regulation of neurofilament dynamics by phosphorylation","volume":"27","author":"Shea","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0310","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00441-012-1362-3","article-title":"Axonal degeneration as a therapeutic target in the CNS","volume":"349","author":"Lingor","year":"2012","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0315","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1212\/01.wnl.0000203120.85850.54","article-title":"Axonal damage markers in cerebrospinal fluid are increased in ALS","volume":"66","author":"Brettschneider","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0320","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1468-1331.2012.03777.x","article-title":"Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression","volume":"19","author":"Tortelli","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0325","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1212\/WNL.52.5.1090","article-title":"Neurofilament protein levels in CSF are increased in dementia","volume":"52","author":"Rosengren","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0330","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.54.10.1960","article-title":"Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD","volume":"54","author":"Sj\u00f6gren","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0335","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0047-6374(01)00303-7","article-title":"Pathophysiological aspects of frontotemporal dementia\u2014emphasis on cytoskeleton proteins and autoimmunity","volume":"122","author":"Sj\u00f6gren","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0340","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/jnnp.2006.107326","article-title":"CSF neurofilament proteins in the differential diagnosis of dementia","volume":"78","author":"de Jong","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0345","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2377-13-54","article-title":"Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia","volume":"13","author":"Landqvist Wald\u00f6","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0350","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.24052","article-title":"Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration","volume":"75","author":"Scherling","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0355","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000099473","article-title":"CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls","volume":"23","author":"Pijnenburg","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0365","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2009.07.007","article-title":"Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders","volume":"16","author":"Constantinescu","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0370","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1353-8020(00)00083-3","article-title":"CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes","volume":"8","author":"Holmberg","year":"2001","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0375","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mds.870130116","article-title":"Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease","volume":"13","author":"Holmberg","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0380","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0385","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2011.08.012","article-title":"Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes","volume":"18","author":"Bech","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0390","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neurobiolaging.2006.03.010","article-title":"CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease","volume":"28","author":"Abdo","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0395","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000091436","article-title":"The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease","volume":"21","author":"Brettschneider","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0400","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/mds.21124","article-title":"Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes","volume":"21","author":"Brettschneider","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0405","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","article-title":"Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS","volume":"77","author":"Ash","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0410","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.neuron.2014.07.041","article-title":"Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD\/ALS","volume":"83","author":"Su","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0415","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jb\/mvq044","article-title":"Regulatory mechanisms involved in the control of ubiquitin homeostasis","volume":"147","author":"Kimura","year":"2010","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0420","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbagrm.2010.07.006","article-title":"Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease","volume":"1809","author":"Hegde","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0425","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF00310917","article-title":"Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid","volume":"82","author":"Wang","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(94)91757-4","article-title":"Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels","volume":"639","author":"Kudo","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1041610294001584","article-title":"Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia","volume":"6","author":"Blennow","year":"1994","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0440","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20639","article-title":"Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers","volume":"58","author":"Iqbal","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0445","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2010.06.075","article-title":"Cerebrospinal fluid profile of amyloid \u03b242 (A\u03b242), hTau and ubiquitin in North Indian Alzheimer's disease patients","volume":"487","author":"Kandimalla","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0450","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1021\/pr5006058","article-title":"Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration","volume":"13","author":"Oeckl","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0455","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/pmic.200900246","article-title":"Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt\u2013Jakob disease","volume":"10","author":"Steinacker","year":"2010","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0304-3940(92)90854-Z","article-title":"Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt\u2013Jakob disease","volume":"139","author":"Manaka","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0465","doi-asserted-by":"crossref","first-page":"892749","DOI":"10.1155\/2012\/892749","article-title":"The role of deubiquitinating enzymes in synaptic function and nervous system diseases","volume":"2012","author":"Kowalski","year":"2012","journal-title":"Neural. Plast."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0470","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.parkreldis.2014.01.011","article-title":"CSF \u03b1-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders","volume":"20","author":"Mondello","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0475","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0480","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-2009-0955","article-title":"Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders","volume":"16","author":"Spies","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0485","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","article-title":"Cerebrospinal fluid Tau\/\u03b1-synuclein ratio in Parkinson's disease and degenerative dementias","volume":"26","author":"Parnetti","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0490","doi-asserted-by":"crossref","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0495","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nbd.2011.08.003","article-title":"Post mortem cerebrospinal fluid \u03b1-synuclein levels are raised in multiple system atrophy and distinguish this from the other \u03b1-synucleinopathies, Parkinson's disease and dementia with Lewy bodies","volume":"45","author":"Foulds","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0500","doi-asserted-by":"crossref","first-page":"430.e1-3","DOI":"10.1016\/j.neurobiolaging.2010.12.001","article-title":"CSF \u03b1-synuclein does not differentiate between parkinsonian disorders","volume":"33","author":"Aerts","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0505","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0510","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0515","doi-asserted-by":"crossref","first-page":"a009415","DOI":"10.1101\/cshperspect.a009415","article-title":"Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways","volume":"2","author":"Cookson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0520","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.parkreldis.2012.03.013","article-title":"The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes","volume":"18","author":"Salvesen","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0525","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.freeradbiomed.2013.05.027","article-title":"SOD2 in mitochondrial dysfunction and neurodegeneration","volume":"62","author":"Flynn","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0530","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/1531-8249(200004)47:4<524::AID-ANA19>3.0.CO;2-5","article-title":"Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases","volume":"47","author":"Aoyama","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0535","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0006-8993(02)02244-8","article-title":"Expression and activity of antioxidants in the brain in progressive supranuclear palsy","volume":"930","author":"Cantuti-Castelvetri","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0540","doi-asserted-by":"crossref","first-page":"939786","DOI":"10.1155\/2013\/939786","article-title":"The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia","volume":"2013","author":"Ridolfi","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0545","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1212\/01.wnl.0000191324.08289.9d","article-title":"Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration","volume":"66","author":"Galimberti","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0550","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00415-008-0737-6","article-title":"Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration","volume":"255","author":"Galimberti","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0555","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/jnnp.2003.019422","article-title":"Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications","volume":"75","author":"Sj\u00f6gren","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0560","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3233\/JAD-2010-1309","article-title":"Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline","volume":"19","author":"Comi","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0565","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0891988706286226","article-title":"IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia","volume":"19","author":"Rentzos","year":"2006","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0570","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","article-title":"Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment","volume":"119","author":"Hu","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0575","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0404.1994.tb01631.x","article-title":"Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy","volume":"89","author":"Yamada","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0580","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/mds.25589","article-title":"The glial marker YKL-40 is decreased in synucleinopathies","volume":"28","author":"Olsson","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0585","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e318200d78d","article-title":"Novel CSF biomarkers for frontotemporal lobar degenerations","volume":"75","author":"Hu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0590","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1034\/j.1600-0404.2002.01125.x","article-title":"Hepatocyte growth factor in cerebrospinal fluid in neurologic disease","volume":"106","author":"Tsuboi","year":"2002","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0595","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jnr.10554","article-title":"Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease","volume":"72","author":"S\u00e1ez-Valero","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0600","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1073\/pnas.0601279103","article-title":"Reelin expression and glycosylation patterns are altered in Alzheimer's disease","volume":"103","author":"Botella-L\u00f3pez","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0605","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)00701-5","article-title":"Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia","volume":"235","author":"Green","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0610","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(02)00968-0","article-title":"Abeta peptide 1\u201342, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia","volume":"333","author":"Maeck","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0615","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(02)01257-0","article-title":"Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease","volume":"336","author":"Petzold","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0620","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0625","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark. Med"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000089137","article-title":"Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias","volume":"21","author":"Blasko","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0635","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JAD-2009-1019","article-title":"MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels","volume":"17","author":"Galimberti","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0640","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2006.05.063","article-title":"Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia","volume":"249","author":"Rentzos","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0645","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/mds.22895","article-title":"Differential pattern of brain-specific CSF proteins tau and amyloid-\u03b2 in Parkinsonian syndromes","volume":"25","author":"S\u00fcssmuth","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0650","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, beta-amyloid(1\u201342) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sj\u00f6gren","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0655","first-page":"167","article-title":"Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration","volume":"4","author":"Edvinsson","year":"1993","journal-title":"Dementia"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0660","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0006-8993(89)91648-X","article-title":"Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear palsy","volume":"479","author":"Iadarola","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0665","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2010.02.004","article-title":"Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation","volume":"221","author":"Ernst","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0670","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/jnnp.2003.026013","article-title":"Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus?","volume":"75","author":"Brettschneider","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0675","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1600-0404.1992.tb05067.x","article-title":"CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy","volume":"86","author":"Litvan","year":"1992","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0680","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00002093-199601040-00005","article-title":"Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia","volume":"10","author":"Minthon","year":"1996","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0685","first-page":"93","article-title":"Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?","volume":"23","author":"Palumbo","year":"2008","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0690","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2006.08.004","article-title":"CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration","volume":"250","author":"Yasui","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0695","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000106636","article-title":"Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia","volume":"8","author":"Minthon","year":"1997","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0700","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-2009-1167","article-title":"Measurement of ERK 1\/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form","volume":"18","author":"Klafki","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0705","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neulet.2006.06.011","article-title":"Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases","volume":"404","author":"Brettschneider","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0710","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clinbiochem.2003.11.012","article-title":"Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia","volume":"37","author":"Diamandis","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0715","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000315539","article-title":"Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease","volume":"30","author":"Ikeuchi","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0720","doi-asserted-by":"crossref","first-page":"e74453","DOI":"10.1371\/journal.pone.0074453","article-title":"Leucine-rich \u03b12-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex","volume":"8","author":"Miyajima","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2014.12.010_bb0725","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2007.07.009","article-title":"Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation","volume":"189","author":"Ernst","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0730","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1258\/acb.2009.009130","article-title":"CSF levels of PSA and PSA\u2013ACT complexes in Alzheimer's disease","volume":"46","author":"Mulder","year":"2009","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0735","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/archneurol.2011.3558","article-title":"Contribution of cerebrospinal fluid thymosin \u03b24 levels to the clinical differentiation of Creutzfeldt\u2013Jakob disease","volume":"69","author":"Le Pera","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0740","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3233\/JAD-122410","article-title":"Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease","volume":"37","author":"Sorensen","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2014.12.010_bb0745","first-page":"631","article-title":"Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease","volume":"47","author":"Yamada","year":"1993","journal-title":"Jpn. J. Psychiatry Neurol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963914003264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963914003264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:48:39Z","timestamp":1761608919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963914003264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":148,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1570963914003264"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2014.12.010","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbapap.2014.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}